Related Experiment Video
Updated: Sep 10, 2025
08:31
A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
4.0K
Optimizing antithrombotic therapy following mitral valve repair: a comprehensive network meta-analysis
Mohamed Ibrahim Gbreel1,2, Mohamed Hamouda Elkasaby3, Marwa Hassan4
1Faculty of Medicine and Surgery, October 6 University, Giza, Egypt.
BMC Cardiovascular Disorders
|August 23, 2025
Summary
Oral anticoagulants (OACs) reduce bleeding risk after mitral valve repair compared to antiplatelet therapies. Vitamin K antagonists (VKAs) and OACs plus single antiplatelet therapy (SAPT) may lower thromboembolic events, but further trials are needed.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Pharmacology
Background:
- Mitral regurgitation (MR) requires repair, with significant thromboembolic risks post-surgery.
- Current guidelines for postoperative anticoagulation therapy after mitral valve repair (MVR) lack consistency.
- Antithrombotic medication strategies post-MVR require comparative analysis.
Purpose of the Study:
- To systematically review and compare antithrombotic medications used after mitral valve repair (MVR).
- To assess the efficacy and safety of different antithrombotic strategies in MVR patients.
Main Methods:
- Systematic literature search of multiple databases (PubMed, Scopus, etc.) until June 2024.
- Inclusion of 12 cohort studies (20,644 participants) from 2008-2022.
- Quality assessment using the Newcastle-Ottawa scale and statistical analysis with R software.
Main Results:
- Oral anticoagulants (OACs) demonstrated a significantly lower bleeding risk compared to single antiplatelet therapy (SAPT).
- No significant differences in thromboembolic events, stroke, or transient ischemic attacks (TIA) were observed between SAPT and vitamin K antagonists (VKA).
- Six-month mortality rates were comparable between SAPT and VKA, with some heterogeneity noted.
Conclusions:
- OACs are associated with reduced bleeding risk post-MVR compared to antiplatelet agents.
- VKAs and combined OAC + SAPT may offer benefits in reducing thromboembolic events.
- Individualized antithrombotic therapy is recommended, emphasizing the need for further randomized controlled trials.
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
01:25Mitral Regurgitation III: Medical Management
30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30
01:22Mitral Valve Prolapse II: Assessment and Management
39
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
39
01:27Mitral Stenosis IV: Nursing Management
45
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
45
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:28Mitral Regurgitation IV: Nursing Management
81
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
81